41 research outputs found
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.
The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had ≥10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9% between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors, <10 positive lymph nodes, and smaller tumor size. HER2 status did not affect survival probability. Adjuvant HDC with AHSCT has a low mortality rate and provides impressive long-term survival rates in patients with high-risk BC. Our results suggest that this treatment modality should be considered in selected high-risk BC patients and further investigated in clinical trials
Gender Asymmetry in Okun's Law in the Four PIGS Countries
AbstractCentred on the four PIGS countries (Portugal, Italy, Greece and Spain) and using the quarterly data from Q2/1998 until Q4/2014, the paper investigates whether there exists gender asymmetries in Okun's law and whether male unemployment reacts identically to economic fluctuations as female unemployment does. Whilst the trend components of output, male and female unemployment are estimated with the aid of the HP filter, Okun's relationships are modelled in the SVAR framework assuming that cyclical fluctuations of the economy and the labour market with both male and female labour force are endogenous. It is established that gender is indeed a factor that makes the respective segments of the labour market respond slightly differently to changes in real output
Age-related decreased inhibitory vs. excitatory gene expression in the adult autistic brain
Contains fulltext :
135935.pdf (publisher's version ) (Open Access
Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
Complete remission before allo-transplantation is crucial for improving survival of acute phase chronic myeloid leukemia
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
Homozygous Mutations in TBC1D23 Lead to a Non-degenerative Form of Pontocerebellar Hypoplasia
Pontocerebellar hypoplasia (PCH) represents a group of recessive
developmental disorders characterized by impaired growth of the pons and
cerebellum, which frequently follows a degenerative course. Currently,
there are 10 partially overlapping clinical subtypes and 13 genes known
mutated in PCH. Here, we report biallelic TBC1D23 mutations in six
individuals from four unrelated families manifesting a non-degenerative
form of PCH. In addition to reduced volume of pons and cerebellum,
affected individuals had microcephaly, psychomotor delay, and ataxia. In
zebrafish, tbc1d23 morphants replicated the human phenotype showing
hindbrain volume loss. TBC1D23 localized at the trans-Golgi and was
regulated by the small GTPases Arl1 and Arl8, suggesting a role in
trans-Golgi membrane trafficking. Altogether, this study provides a
causative link between TBC1D23 mutations and PCH and suggests a less
severe clinical course than other PCH subtypes
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies. As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient. In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease. In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas